Oral Hypoglycemic Agents

New England Journal of Medicine

Volumn 321, Issue 18, 1989, Pages 1231-1245

  Oates, John A ^a   Wood, Alastair J j ^a   Gerich, John E ^b  

^a University of Pittsburgh School of Medicine ^*

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETOHEXAMIDE; BUFORMIN; CHLORPROPAMIDE; GLIBENCLAMIDE; GLIPIZIDE; METFORMIN; ORAL ANTIDIABETIC AGENT; PHENFORMIN; TOLAZAMIDE; TOLBUTAMIDE;

ADULT; AGE; GASTROINTESTINAL DISEASE; HEMATOLOGIC DISEASE; HUMAN; HYPOGLYCEMIA; HYPONATREMIA; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; REVIEW; SKIN DISEASE;

ADMINISTRATION, ORAL; DIABETES MELLITUS; HUMAN; HYPOGLYCEMIC AGENTS; SUPPORT, U.S. GOV'T, P.H.S.;

EID: 0024465303     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJM198911023211805     Document Type: Review

References (302)

1. Kennedy DL, Piper JM, Baum C. Trends in use of oral hypoglycemic agents, 1964–1986. Diabetes Care 1988; 11: 558–62.
2. Eisenbarth GS. Type I diabetes mellitus: a chronic autoimmune disease. N Engl J Med 1986; 314: 1360–8.
3. DeFronzo RA, Ferrannini E, Koivisto V. New concepts in the pathogenesis and treatment of noninsulin-dependent diabetes mellitus. Am J Med 1983; 74: Suppl 1A: 52–81.
4. Turner RC, Mathews DR, Clark A, O'Rahilly S, Rudenski AS, Levy J. Pathogenesis of NIDDM — a disease of deficient insulin secretion. Baillieres Clin Endocrinol Metab 1988; 2: 327–42.
5. Gerich JE. Role of insulin resistance in the pathogenesis of type 2 (noninsulin-dependent) diabetes mellitus. Baillieres Clin Endocrinol Metab 1988; 2: 307–26.
6. Lillioja S, Mott DM, Howard BV, et al. Impaired glucose tolerance as a disorder of insulin action: longitudinal and cross-sectional studies in Pima Indians. N Engl J Med 1988; 318: 1217–25.
7. Groop LC, Bottazzo GF, Doniach D. Islet cell antibodies identify latent type I diabetes in patients aged 35–75 years at diagnosis. Diabetes 1986; 35: 237–41.
8. Irvine WJ, Sawers JSA, Feek CM, Prescott RJ, Duncan LJP. The value of islet cell antibody in predicting secondary failure to oral hypoglycaemic agent therapy in diabetes mellitus. J Clin Lab Immunol 1979; 2: 23–6.
9. Yki-Jarvinen H, Koivisto VA. Effects of body composition on insulin sensitivity. Diabetes 1983; 32: 965–9.
10. Bogardus C, Lillioja S, Mott D, Hollenbeck C, Reaven G. Relationship between degree of obesity and in vivo insulin action in man. Am J Physiol 1985; 248: E286–E291.
11. Savage PJ, Bennion LJ, Bennett PH. Normalization of insulin and glucagon secretion in ketosis-resistant diabetes mellitus with prolonged diet therapy. J Clin Endocrinol Metab 1979; 49: 830–3.
12. Hadden DR, Montgomery DA, Skelly RJ, et al. Maturity onset diabetes mellitus: response to intensive dietary management. Br Med J 1975; 3: 276–8.
13. Barnard RJ, Lattimore L, Holly RG, Cherny S, Pritikin N. Response of non-insulin-dependent diabetic patients to an intensive program of diet and exercise. Diabetes Care 1982; 5: 370–4.
14. Stanik S, Marcus R. Insulin secretion improves following dietary control of plasma glucose in severely hyperglycemic obese patients. Metabolism 1980; 29: 346–50.
15. Perley MJ, Kipnis DM. Plasma insulin responses to oral and intravenous glucose: studies in normal and diabetic subjects. J Clin Invest 1967; 46: 1954–62.
16. Temple RC, Carrington CA, Luzio SD, et al. Insulin deficiency in noninsulin-dependent diabetes. Lancet 1989; 1: 293–5.
17. O'Rahilly SP, Nugent Z, Rudenski AS, et al. Beta-cell dysfunction, rather than insulin insensitivity, is the primary defect in familial type 2 diabetes. Lancet 1986; 2: 360–4.
18. Yki-Jarvinen H, Helve E, Koivisto VA. Hyperglycemia decreases glucose uptake in type I diabetes. Diabetes 1987; 38: 892–6.
19. Rossetti L, Smith D, Shulman G, Papachristou D, DeFronzo R. Correction of hyperglycemia with phlorizin normalizes tissue sensitivity to insulin in diabetic rats. J Clin Invest 1987; 79: 1510–5.
20. Leahy JL, Cooper H, Deal DA, Weir GC. Chronic hyperglycemia is associated with impaired glucose influence on insulin secretion: a study of normal rats using chronic in vivo glucose infusions. J Clin Invest 1986; 77: 908–15.
21. Imamura T, Koffler M, Helderman JH, et al. Severe diabetes induced in subtotally depancreatized dogs by sustained hyperglycemia. Diabetes 1988; 37: 600–9.
22. Rifkin H, ed. Physician's guide to noninsulin-dependent (type II) diabetes: diagnosis and treatment. 2nd ed. Alexandria, Va.: American Diabetes Association, 1988.
23. Alberti K, Gries F. Management of non-insulin-dependent diabetes mellitus in Europe: a consensus view. Diabetic Med 1988; 5: 275–81.
24. Mauer SM, Steffes MW, Sutherland DE, Najarian S, Michael AF, Brown DM. Studies on the rate of regression of glomerular lesions in diabetic rats treated with pancreatic islet transplantation. Diabetes 1975; 24: 280–5.
25. Engerman R, Bloodworth JM Jr, Nelson S. Relationship of microvascular disease in diabetes to metabolic control. Diabetes 1977; 26: 760–9.
26. Greene DA, Lattimer SA, Sima AA. Are disturbances of sorbitol, phosphoinositide, and Na+-K+-ATPase regulation involved in pathogenesis of diabetic neuropathy? Diabetes 1988; 37: 688–93.
27. Brownlee M, Cerami A, Vlassara H. Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications. N Engl J Med 1988; 318: 1315–21.
28. Rushforth NB, Miller M, Bennett PH. Fasting and two-hour, post-load glucose levels for the diagnosis of diabetes: the relationship between glucose levels and complications of diabetes in the Pima Indians. Diabetologia 1979; 16: 373–9.
29. Knuiman MW, Welborn TA, McCann VJ, Stanton KG, Constable IJ. Prevalence of diabetic complications in relation to risk factors. Diabetes 1986; 35: 1332–9.
30. Pirart J. Diabetes mellitus and its degenerative complications: a prospective study of 4,400 patients observed between 1947 and 1973. Diabetes Care 1978; 1: 168–88, 252–63.
31. Mauer SM, Barbosa J, Vernier RL, et al. Development of diabetic vascular lesions in normal kidneys transplanted into patients with diabetes mellitus. N Engl J Med 1976; 295: 916–20.
32. Feldt-Rasmussen B, Mathiesen E, Deckert T. Effect of two years of strict metabolic control on progression of incipient nephropathy in insulin-dependent diabetes. Lancet 1986; 2: 1300–4.
33. Dahl-Jorgensen K, Brinchmann-Hansen O, Hanssen KF, et al. Effect of near normoglycaemia for two years on progression of early diabetic retinopathy, nephropathy and neuropathy: the Oslo study. Br Med J 1986; 293: 1195–9.
34. Krolewski AS, Warram JH, Rand LI, Kahn CR. Epidemiologic approach to the etiology of type I diabetes mellitus and its complications. N Engl J Med 1987; 317: 1390–8.
35. Pyorala K. Relationship of glucose tolerance and plasma insulin to the incidence of coronary heart disease: results from two population studies in Finland. Diabetes Care 1979; 2: 131–41.
36. Fuller JH, Shipley MJ, Rose G, Jarrett RJ, Keen H. Mortality from coronary heart disease and stroke in relation to degree of glycaemia: the Whitehall Study. Br Med J 1983; 287: 867–70.
37. Persson G. Cardiovascular complications in diabetics and subjects with reduced glucose tolerance. Acta Med Scand Suppl 1977; 605: 7–48.
38. Barrett-Connor E, Wingard DL, Criqui MH, Suarez L. Is borderline fasting hyperglycemia a risk factor for cardiovascular death? J Chronic Dis 1984; 37: 773–9.
39. Donahue RP, Abbott RD, Reed DM, Yano K. Postchallenge glucose concentration and coronary heart disease in men of Japanese ancestry: Honolulu Heart Program. Diabetes 1987; 36: 689–92.
40. Tchobroutsky G. Relation of diabetic control in development of microvascular complications. Diabetologia 1978; 15: 143–52.
41. Hanssen KF, Dahl-Jorgensen K, Lauritzen T, Feldt-Rasmussen B, Brenchmann-Hansen O, Deckert T. Diabetic control and microvascular complications: the near normoglycemic experience. Diabetologia 1986; 29: 677–84.
42. Martin DB. Type II diabetes: insulin versus oral agents. N Engl J Med 1986; 314: 1314–5.
43. Heine RJ. Insulin treatment of non-insulin-dependent diabetes mellitus. Baillieres Clin Endocrinol Metab 1988; 2: 477–92.
44. Melander A. Sulphonylureas in the treatment of non-insulin-dependent diabetes. Baillieres Clin Endocrinol Metab 1988; 2: 443–53.
45. UK prospective study of therapies of maturity-onset diabetes I. Effect of diet, sulphonylurea, insulin or biguanide therapy on fasting plasma glucose and body weight over one year. Diabetologia 1983; 24: 404–11.
46. Wing RR. Koeske R, Epstein LH, Nowalk MP, Gooding W, Becker D. Long-term effects of modest weight loss in type II diabetic patients. Arch Intern Med 1987; 147: 1749–53.
47. West KM. Diet therapy of diabetes: an analysis of failure. Ann Intern Med 1973; 79: 425–34.
48. Council on Scientific Affairs. Hypoglycemic treatment: guidelines for the non-insulin-dependent diabetic. JAMA 1980; 243: 2078–9.
49. Nattrass M. Treatment of type H diabetes. Br Med J 1986; 292: 1033–4.
50. Tattersall RB, Scott AR. When to use insulin in the maturity onset diabetic. Postgrad Med J 1987; 63: 859–64.
51. Levine R. Sulfonylureas: background and development of the field. Diabetes Care 1984; 7: Suppl 1: 3–7.
52. Jackson JE, Bressler R. Clinical pharmacology of sulfonylurea hypoglycaemic agents. Drags 1981; 22: 211–45, 295–320.
53. Skillman TG, Feldman JM. The pharmacology of sulfonylureas. Am J Med 1981; 70: 361–72.
54. Ruiz CL, Silva LL, Libenson L. Contribucion al estudio sobre la composicion quimica de la insulina: estudio de algunos cuerpos sintéticos sulfurados con acción hipoglucemiante. Rev Soc Argentina Biol 1930; 6: 134–41.
55. Janbon M, Chaptal J, Vedel A, Schoop J. Accidents hypoglycemiques graves par un sulfamido-thiadiazoe (le VK 57 ou 2254 RP). Montpellier Med 1942; 441: 21–2.
56. Loubatieres A. Relations entre la structure moleculaire et 1'activate hypoglycemiante des aminosulfamides hypoglycemiantes. Arch Int Physiol 1944; 54: 174–7.
57. Loubatieres Relation de mécanisme de faction hypoglycèmiante du p-aminobenzènesulfamidoisopropyl-thiodiazol (2254 R.P.). Comptes Rendus Soc Biol 1944; 138: 766–7.
58. Loubatieres Etude physiologique et pharmacodynamique de certains derives sulfamides hypoglycemiants. Arch Int Physiol 1946; 54: 174–7.
59. Franke H, Fuchs J. Ein neues antidiabetisches prinzip: Ergebnisse klinischer Untersuchungen. Dtsch Med Wochenschr 1955; 80: 1449–52.
60. Achelis JD, Hardebeck K. Uber eine neue blutzuckersenkende Substanz: Vorlänfige Mitteilung. Dtsch Med Wochenschr 1955; 80: 1452–5.
61. Betram P, Bendfeldt E, Otto H. Über ein wirksames perorales antidiabeticum (BZ 55). Dtsch Med Wochenschr 1955; 80: 1455–60.
62. A study of the effects of hypoglycemia agents on vascular complications in patients with adult-onset diabetes. VI. Supplementary report on nonfatal events in patients treated with tolbutamide. Diabetes 1976; 25: 1129–53.
63. Kolata GB. Controversy over study of diabetes drugs continues for nearly a decade. Science 1979; 203: 986–90.
64. Schor S. The University Group Diabetes Program: a statistician looks at the mortality results. JAMA 1971; 217: 1673–5.
65. Feinstein AR. Clinical biostatistics. VIII. An analytic appraisal of the University Group Diabetes Program (UGDP) study. Clin Pharmacol Ther 1971; 12: 167–91.
66. Seltzer HS. A summary of criticisms of the findings and conclusions of the University Group Diabetes Program (UGDP). Diabetes 1972; 21: 976–9.
67. Kilo C, Miller JP, Williamson JR. The crux of the UGDP: spurious results and biologically inappropriate data analysis. Diabetologia 1980; 18: 179–85.
68. American Diabetes Association. Policy statement: the UGDP controversy. Diabetes Care 1979; 2: 1–3.
69. Paasikivi J, Wahlberg F. Preventive tolbutamide treatment and arterial disease in mild hyperglycaemia. Diabetologia 1971; 7: 323–7.
70. Ohneda A, Maruhama Y, Itabashi H, et al. Vascular complications and long-term administration of oral hypoglycemic agents in patients with diabetes mellitus. Tohoku J Exp Med 1978; 124: 205–22.
71. Grodsky GM, Epstein GH, Fanska R, Karam JH. Pancreatic action of the sulfonyl-ureas. Fed Proc 1977; 36: 2714–9.
72. Ferner RE, Chaplin S. The relationship between the pharmacokinetics and the pharmacodynamic effects of oral hypoglycaemic drugs. Clin Pharmacokinet 1987; 12: 379–401.
73. Boyd AE III. Sulfonylurea receptors, ion channels, and fruit flies. Diabetes 1988; 37: 847–50.
74. Schmid-Antomarchi H, De Weille J, Fosset M, Lazdunski M. The receptor for the antidiabetic sulfonylureas controls the activity of the ATP-modulated K+ channel in insulin-secreting cells. J Biol Chem 1987; 262: 15840–4.
75. Gaines KL, Hamilton S, Boyd AE III. Characterization of the sulfonylurea receptor on beta cell membranes. J Biol Chem 1988; 263: 2589–92.
76. Oberwetter JM, Boyd AE III. High K+ rapidly stimulates Ca2 +-dependent phosphorylation of three proteins concomitant with insulin secretion from HIT cells. Diabetes 1987; 36: 864–71.
77. Zawalich KC, Zawalich WS. Sustained agonist-induced increases in phosphoinositide (PI) hydrolysis are responsible for pancreatic beta cell memory. Diabetes 1988; 37: Suppl 1: 42A. abstract.
78. Ostenson CC, Nylen A, Grill V, Gutniak M, Efendic S. Sulfonylureainduced inhibition of glucagon secretion from the perfused rat pancreas: evidence for a direct, nonparacrine effect. Diabetologia 1986; 29: 861–7.
79. Laube H, Fussganger R, Gobema R, et al. Effects of tolbutamide on insulin and glucagon secretion of the isolated perfused rat pancreas. Horm Metab Res 1971; 3: 238–42.
80. Ohneda A, Sato M, Matsuda K, et al. Suppression of pancreatic glucagon secretion by tolbutamide in dogs. Horm Metab Res 1974; 6: 478–83.
81. Samols E, Tyler JM, Mialhe P. Suppression of pancreatic glucagon release by the hypoglycaemic sulphonylureas. Lancet 1969; 1: 174–6.
82. Kajinuma H, Kuzuya TT, Ide T. Effects of hypoglycemic sulfonamides on glucagon and insulin secretion in ducks and dogs. Diabetes 1974; 23: 412–7.
83. Pfeiffer EF. Current pathophysiological and clinical aspects of the mode of action of blood glucose lowering sulfonamides. Acta Diabetol Lat 1969; 6: Suppl 1: 477–502.
84. Tsalikian E, Dunphy TW, Bohannon NV, et al. The effect of chronic oral antidiabetic therapy on insulin and glucagon responses to a meal. Diabetes 1977; 26: 314–21.
85. Hayes JR, Callaghan S, Grant AP. The effect of glibenclamide treatment on the insulin and glucagon responses to oral glucose and galactose in maturity onset diabetics. Diabete Metab 1979; 5: 207–11.
86. Pfeifer MA, Beard JC, Halter JB, Judzewitsch R, Best JD, Porte D Jr. Suppression of glucagon secretion during a tolbutamide infusion in normal and noninsulin-dependent diabetic subjects. J Clin Endocrinol Metab 1983; 56: 586–91.
87. Frier B, Ashby JP, Nairn IM, Baird JD. Plasma insulin, C-peptide and glucagon concentrations in patients with insulin-independent diabetes treated with chlorpropamide. Diabete Metab 1981; 7: 45–9.
88. Lecomte MJ, Luyckx AS, Lefebvre PJ. Plasma glucagon and clinical control of maturity-onset type diabetes: effects of diet, placebo and glipizide. Diabete Metab 1977; 3: 239–43.
89. Unger RH, Aguilar-Parada E, Muller WA, Eisentraut AM. Studies of pancreatic alpha cell function in normal and diabetic subjects. J Clin Invest 1970; 49: 837–48.
90. Pek S, Fajans SS, Floyd JC Jr, Knopf RF, Conn JW. Failure of sulfonylureas to suppress plasma glucagon in man. Diabetes 1972; 21: 216–23.
91. Joost HG. Extrapancreatic effects of hypoglycemic sulfonylureas: still a controversial issue. Trends Pharmacol Sci 1985; 6: 239–41.
92. Beck-Nielsen H, Hother-Nielsen O, Pedersen O. Mechanism of action of sulfonylureas with special reference to the extrapancreatic effect: an overview. Diabetic Med 1988; 5: 613–20.
93. Chen KK, Anderson RC, Maze N. Hypoglycemic action of sulfanilamidocyclopropylthiazole in rabbits, and its reversal by alloxan. Proc Soc Exp Biol Med 1946; 63: 483–7.
94. La Barre J, Reuse J. A propos de faction hypoglycémiante de certains dérivés sulfamidés. Arch Neerl Physiol Homme Anim 1947; 28: 475–80.
95. Houssay BA, Penhos JC. Action of the hypoglycemic sulfonyl compounds in hypophysectomized, adrenalectomized and depancreatized animais. Metabolism 1956; 5: 727–32.
96. Mirsky IA, Perisutti G, Jinks R. Ineffectiveness of sulfonylureas in alloxan diabetic rats. Proc Soc Exp Biol Med 1956; 91: 475–7.
97. Fritz IB, Morton JV, Weinstein M, Levine R. Studies on the mechanism of action of the sulfonylureas. Metabolism 1956; 5: 744–8.
98. Caren R, Corbo L. The potentiation of exogenous insulin by tolbutamide in depancreatized dogs. J Clin Invest 1957; 36: 1546–50.
99. Kirtley WR, Ridolfo AS, Root MA, Anderson RC. Clinical and pharmacological effects of substance BZ-55 in diabetes: (p-aminophenylsulfonyl butylcarbamide). Diabetes 1956; 5: 351–7.
100. Ricketts HT, Wildberger HL, Schmid H. Long-term studies of sulfonylureas in totally depancreatized dogs. Ann N Y Acad Sci 1957; 71: 170–6.
101. Beyer V, Cordes U, Krall H, Sell G, Schöffling K. Extrapankreatische Wirkungen Von Sulfonylharnstoffen. Arzneimittelforschung 1972; 22: 2167–72.
102. Dolger H. Clinical experience with orinase. Metabolism 1956; 5: 947–52.
103. Friedlander O. Use of tolbutamide in insulin-resistant diabetes: report of a case. N Engl J Med 1957; 257: 11–4.
104. Fabrykant M. Favorable effects of supplemental orinase in insulin-treated labile diabetes. Metabolism 1957; 6: 509–17.
105. Goetz FC, Gilbettsen AS, Josephson V. Acute effects of orinase on peripheral glucose utilization. Metabolism 1956; 5: 788–800.
106. Ward EA, Ward GM, Turner RC. Effect of sulfonylurea on insulin secretion and glucose control in insulin-treated diabetics. Br Med J 1981; 283: 278.
107. Grunberger G, Ryan J, Gorden P. Sulfonylureas do not affect insulin binding or glycemic control in insulin-dependent diabetics. Diabetes 1982; 31: 890–6.
108. Ratzmann KP, Schulz B, Heinke P, Besch W. Tolbutamide does not alter insulin requirement in Type 1 (insulin-dependent) diabetes. Diabetologia 1984; 27: 8–12.
109. Burke BJ, Hartog M, Waterfield MR. Improved diabetic control in insulin-dependent diabetes treated with insulin and glibenclamide. Acta Endocrinol 1984; 107: 70–7.
110. Goldman J, Tamayo RC, Whitehouse FW, Kahkonen DM. Effect of glyburide on metabolic control and insulin binding in insulin-dependent diabetes mellitus. Diabetes Care 1984; 7: Suppl: 106–12.
111. Keller U, Muller R, Berger W. Sulfonylurea therapy fails to diminish insulin resistance in type I diabetic subjects. Horm Metab Res 1986; 18: 599–603.
112. Bieger W, Dlugosch R, Rettenmeier A, et al. Trial of sulfonylurea in combination with insulin in the therapy of diabetes type I and II: evidence against a primary extrapancreatic receptor effect. Klin Wochenschr 1984; 62: 631–9.
113. Duncan GG, Joiner CL, Lee CT. Methods of selection of diabetic patients sensitive to sulfonylurea compounds. Metabolism 1956; 5: 964–71.
114. Kabadi UM, Birkenholz MR. Improved metabolic control in insulin-dependent diabetes mellitus with insulin and tolazamide. Arch Intern Med 1988; 148: 1745–9.
115. Pontiroli AE, Alberetto M, Bertoletti A, Baio G, Pozza G. Sulfonylureas enhance in vivo the effectiveness of insulin in type I (insulin-dependent) diabetes mellitus. Horm Metab Res 1984; 16: Suppl: 167–70.
116. Pemet A, Trimble ER, Kuntschen F, Assal JP, Hahn C, Renold A. Sulfonylureas in insulin-dependent (type I) diabetes: evidence for an extrapancreatic effect in vivo. J Clin Endocrinol Metab 1985; 61: 247–51.
117. Garrel DR, Picq R, Bajard L, Harfouche M, Tourniaire J. Acute effects of glyburide on insulin sensitivity in type I diabetic patients. J Clin Endocrinol Metab 1987; 65: 896–900.
118. Reaven G, Dray J. Effect of chlorpropamide on serum glucose and immunoreactive insulin concentrations in patients with maturity-onset diabetes mellitus. Diabetes 1967; 16: 487–92.
119. Feldman JM, Lebovitz HE. Endocrine and metabolic effects of glybenclamide: evidence for an extrapancreatic mechanism of action. Diabetes 1971; 20: 745–55.
120. Duckworth WC, Solomon SS, Kitabchi AE. Effect of chronic sulfonylurea therapy on plasma insulin and proinsulin levels. J Clin Endocrinol Metab 1972; 35: 585–91.
121. Kolterman OG, Gray RS, Shapiro G, Scarlett JA, Griffin J, Olefsky JM. The acute and chronic effects of sulfonylurea therapy in type II diabetic subjects. Diabetes 1984; 33: 346–54.
122. Beck-Nielsen H, Pederson O, Lindskov HO. Increased insulin sensitivity and cellular insulin binding in obese diabetics following treatment with glibenclamide. Acta Endocrinol 1979; 90: 451–62.
123. Olefsky JM, Reaven GM. Effects of sulfonylurea therapy on insulin binding to mononuclear leukocytes of diabetic patients. Am J Med 1976; 60: 89–95.
124. Simonson DC, Fenrannini E, Bevilacqua S, et al. Mechanism of improvement in glucose metabolism after chronic glyburide therapy. Diabetes 1984; 33: 838–45.
125. Groop L, Hamo K, Tolppanen E. The combination of insulin and sulfonylurea in the treatment of secondary drug failure in patients with type II diabetes. Acta Endocrinol 1984; 106: 97–101.
126. Schade DS, Mitchell WJ, Griego G. Addition of sulfonylurea to insulin treatment in poorly controlled type II diabetes: a double-blind, randomized clinical trial. JAMA 1987; 257: 2441–5.
127. Mandarino L, Gerich J. Prolonged sulfonylurea administration decreases insulin resistance and increases insulin secretion in non-insulin-dependent diabetes mellitus: evidence for improved insulin action at a postreceptor site in hepatic as well as extrahepatic tissues. Diabetes Care 1984; 7: Suppl 1: 89–99.
128. Blumenthal SA. Potentiation of the hepatic action of insulin by chlorpropamide. Diabetes 1977; 26: 485–9.
129. Blumenthal SA, Whitmer KR. Hepatic effects of chlorpropamide: inhibition of glucagon-stimulated gluconeogenesis in perfused livers of fasted rats. Diabetes 1979; 28: 646–50.
130. Monge L, Monjena M, Ortega JL, Saper B, Cabello M, Feliu JE. Chlorpropamide raises fractose-2,6-bisphosphate concentration and inhibits gluconeogenesis in isolated rat hepatocytes. Diabetes 1986; 35: 89–96.
131. McGuinness OP, Green DR, Cherrington AD. Glyburide sensitizes perfused rat liver to insulin-induced suppression of glucose output. Diabetes 1987; 36: 472–6.
132. Jacobs DB, Hayes GR, Lockwood DH. Effect of chlorpropamide on glucose transport in rat adipocytes in the absence of changes in insulin binding and receptor-associated tyrosine kinase activity. Metabolism 1987; 36: 548–54.
133. Rogers BJ, Standaert ML, Pollet RJ. Direct effects of sulfonylurea agents on glucose transport in the BC3H–1 myocyte. Diabetes 1987; 36: 1292–6.
134. Wang PH, Beguinot F, Smith RJ. Augmentation of the effects of insulin and insulin-like growth factors I and II on glucose uptake in cultured rat skeletal muscle cells by sulfonylureas. Diabetologia 1987; 30: 797–803.
135. Maloff BL, Lockwood DH. In vitro effects of a sulfonylurea on insulin action in adipocytes: potentiation of insulin-stimulated hexose transport. J Clin Invest 1981; 68: 85–90.
136. Sulfonylurea potentiates insulin-induced recruitment of glucose transport carrier in rat adipocytes, D.B., Jacobs, C.Y., Jung, J Biol Chem, (1985), 260, 2593-2596
137. Patel TB. Effect of sulfonylureas on hepatic fatty acid oxidation. Am J Physiol 1986; 251: E242–E246.
138. McCormick K, Williams MC, Sicoli R, Chen L. Effect of tolazamide on basal ketogenesis, glycogenesis and gluconeogenesis in liver obtained from normal and diabetic rats. Endocrinology 1986; 119: 1268–73.
139. Feldman JM, Lebovitz HE. An insulin dependent effect of chronic tolbutamide administration on the skeletal muscle carbohydrate transport system. Diabetes 1969; 18: 84–95.
140. Rafaelsen OJ. Action of oral antidiabetic drugs on carbohydrate metabolism of isolated rat diaphragm. Metabolism 1959; 8: 195–204.
141. Bloch K, Daturi S, Tommasini R. Effect of glipizide on muscle metabolism in vitro. Acta Endocrinol Suppl (Copenh) 1980; 239: 23–5.
142. Salhanick AI, Konowitz P, Amatruda JM. Potentiation of insulin action by a sulfonylurea in primary cultures of hepatocytes from normal and diabetic rats. Diabetes 1983; 32: 206–12.
143. Dolais-Kitabji J, Alengrin F, Freychet P. Sulfonylureas in vitro do not alter insulin binding or insulin effect on amino acid transport in rat hepatocytes. Diabetologia 1983; 24: 441–4.
144. Cahill GF Jr, Hastings AB, Ashmore J. Effects of substituted sulfonylureas on rat diaphragm and liver tissue. Diabetes 1957; 6: 26–7.
145. Mine T, Kimura S, Ohsawa H, Ogata E. Evidence for direct effect of tolbutamide on hepatic glycogenolysis induced by Ca2+-dependent hormones. Biochem Pharmacol 1986; 35: 3103–7.
146. Mooradian AD. The effect of sulfonylurea on the in vivo tissue uptake of glucose in normal rats. Diabetologia 1987; 30: 120–1.
147. Marshall A, Gingerich RL, Wright PH. Hepatic effect of sulfonylureas. Metabolism 1970; 19: 1046–52.
148. Hosker JP, Burnett MA, Davies EG, Harris EA, Turner RC. Sulfonylurea therapy doubles β-celI response to glucose in type II diabetic patients. Diabetologia 1985; 28: 809–14.
149. Judzewitsch RG, Pfeifer MA, Best JD, Beard JC, Halter JB, Porte D Jr. Chronic chlorpropamide therapy of noninsulin-dependent diabetes augments basal and stimulated insulin secretion by increasing islet sensitivity to glucose. J Clin Endocrinol Metab 1982; 55: 321–8.
150. Bodansky HJ, Medback S, Cudworth AG, Rees LH, de Silva RS. Long term improvement in insulin response with gliclazide treatment. Diabete Metab 1982; 8: 319–22.
151. Elkeles RS, Heding LG, Paisey RB. The long-term effects of chlorpropamide on insulin, C-peptide and proinsulin secretion. Diabetes Care 1982; 5: 427–9.
152. Bolinder J, Ostman J, Arner P. Reversal of insulin resistance in adipose tissue of non-insulin-dependent diabetics by treatment with diet and sulfonylurea. Acta Endocrinol (Copenh) 1985; 108: 85–90.
153. Zinman B, Ogilvie RI. The acute effects of tolbutamide on forearm metabolism. J Clin Endocrinol Metab 1972; 35: 299–306.
154. Butterfield WJH, Arab MMH, Buckle ALJ, et al. The mechanism of action of tolbutamide: observation on the effects of sulfonylureas on peripheral metabolism in man. Diabetes 1962; 11: Suppl: 43–9.
155. Shank WA Jr, Morrison AD. Oral sulfonylureas for the treatment of type II diabetes: an update. South Med J 1986; 79: 337–43.
156. Prendergast BD. Glyburide and glipizide, second-generation oral sulfonylurea hypoglycemic agents. Clin Pharm 1984; 3: 473–85.
157. Melander A. Clinical pharmacology of sulfonylureas. Metabolism 1987; 36: Suppl 1: 12–6.
158. Hansen JM, Christensen LK. Drug interactions with oral sulfonylurea hypoglycaemic drugs. Drugs 1977; 13: 24–34.
159. Brogden RN, Heel RC, Pakes GE, Speight TM, Avery GS. Glipizide: a review of its pharmacologic properties and therapeutic use. Drags 1979; 18: 329–53.
160. Lebovitz H. Clinical utility of oral hypoglycemic agents in the management of patients with noninsulin-dependent diabetes mellitus. Am J Med 1983; 75: Suppl 5B: 94–9.
161. Balant L. Clinical pharmacokinetics of sulphonylurea hypoglycaemic drags. Clin Pharmacokinet 1981; 6: 215–41.
162. Sartor G, Schersten B, Melander A. Effects of glipizide and food intake on the blood levels of glucose and insulin in diabetic patients. Acta Med Scand 1978; 203: 211–4.
163. Balant L, Zahnd GR, Weber F, Fabre J. Behaviour of glibenclamide on repeated administration to diabetic patients. Eur J Clin Pharmacol 1977; 11: 19–25.
164. Sartor G, Lundquist I, Melander A, Schersten B, Wahlin-Boll E. Improved effect of glibenclamide on administration before breakfast. Eur J Clin Pharmacol 1982; 21: 403–8.
165. Crooks MJ, Brown KF. The binding of sulphonylureas to serum albumin. J Pharm Pharmacol 1974; 26: 304–11.
166. Judis J. Binding of sulfonylureas to serum proteins. J Pharm Sci 1972; 61: 89–93.
167. Hsu PL, Ma JK, Luzzi LA. Interactions of sulfonylureas with plasma proteins. J Pharm Sci 1974; 63: 570–3.
168. Sheldon J, Anderson J, Stoner L. Serum concentration and urinary excretion of oral sulfonylurea compounds: relation to diabetic control. Diabetes 1965; 14: 362–7.
169. Scott J, Poffenbarger PL. Pharmacogenetics of tolbutamide metabolism in humans. Diabetes 1979; 28: 41–51.
170. Smith DL, Vecchio TJ, Forist AA. Metabolism of antidiabetic sulfonylureas in man. I. Biological half-lives of thep-Acetylbenzenesulfonylureas, U-18536 and acetohexamide and their metabolites. Metabolism 1965; 14: 229–40.
171. Galloway JA, McMahon RE, Culp HW, Marshall FJ, Young EC. Metabolism, blood levels and rate of excretion of acetohexamide in human subjects. Diabetes 1967; 16: 118–27.
172. Thomas RC, Duchamp DJ, Judy RW, Ikeda GJ. Metabolic fate of tolazamide in man and in the rat. J Med Chem 1978; 21: 725–32.
173. Taylor JA. Pharmacokinetics and biotransformation of chlorpropamide in man. Clin Pharmacol Ther 1972; 13: 710–8.
174. Fuccella LM, Tamassia V, Valzelli G. Metabolism and kinetics of the hypoglycemic agent glipizide in man — comparison with glibenclamide. J Clin Pharmacol New Drugs 1973; 13: 68–75.
175. Schmidt HA, Schoog M, Schweer KH, Winkler E. Pharmacokinetics and pharmacodynamics as well as metabolism following orally and intravenously administered C14-glipizide, a new antidiabetic. Diabetologia 1973; 9: 320–30.
176. Balant L, Fabre J, Loutan L, Samimi H. Does 4-trans-hydroxy-glibenclamide show hypoglycemic activity? Arzneimittelforschung 1979; 29: 162–3.
177. Rupp W, Christ O, Fülberth W. Untersuchungen zur Bioavailability von Glibenclamid. Arzneimittelforschung 1972; 22: 471–3.
178. Fabre J, Balant L, Loutan L, Samimi H. Hypoglycemic activity of the main metabolite of glibenclamide: influence of renal insufficiency. Kidney Int 1978; 13: 435. abstract.
179. Pearson JG, Antal EJ, Raehl CC, et al. Pharmacokinetic disposition of 14C-glyburide in patients with varying renal function. Clin Pharmacol Ther 1986; 39: 318–24.
180. Balant L, Zahnd G, Gorgia A, Schwarz R, Fabre J. Pharmacokinetics of glipizide in man: influence of renal insufficiency. Diabetologia 1973; 9: 331–8.
181. Bernhard H. Long-term observations on oral hypoglycemic agents in diabetes: the effect of carbutamide and tolbutamide. Diabetes 1965; 14: 59–70.
182. Balodimos MC, Camerini-Davalos RA, Marble A. Nine years' experience with tolbutamide in the treatment of diabetes. Metabolism 1966; 11: 957–70.
183. Singer DL, Hurwitz D. Long-term experience with sulfonylureas and placebo. N Engl J Med 1967; 277: 450–6.
184. Schmitt JK, Harriman K, Poole JR. Modification of therapy from insulin to chlorpropamide decreases HDL cholesterol in patients with non-insulindependent diabetes mellitus. Diabetes Care 1987; 10: 692–6.
185. Nathan DM, Roussell A, Godine JE. Glyburide or insulin for metabolic control in non-insulin-dependent diabetes mellitus: a randomized, double-blind study. Ann Intern Med 1988; 108: 334–40.
186. Effects of tolazamide and exogenous insulin on insulin action in patients with non-insulin-dependent diabetes mellitus, R.G., Firth, P.M., Bell, R.A., Rizza, N Engl J Med, (1986), 314, 1280-1286
187. Singer DL, Stewart RC, Hurwitz D. Chlorpropamide in patients on high insulin dosage. N Engl J Med 1961; 265: 823–6.
188. Madsbad S, Krarup T, McNair P, et al. Practical clinical value of C-peptide response to glucagon stimulation in the choice of treatment in diabetes mellitus. Acta Med Scand 1981; 210: 153–6.
189. Rendell M. C-peptide levels as a criterion in treatment of maturity-on set diabetes. J Clin Endocrinol Metab 1983; 57: 1198–206.
190. Sonksen PH, Lowry C, Perkins JR, Lim HS. Non-insulin-dependent diabetes: 10-year outcome in relation to initial response to diet and subsequent sulfonylurea therapy. Diabetes Care 1984; 7: Suppl 1: 59–66.
191. Groop LC, Pelkonen R, Koskimies S, Bottazzo GF, Doniach D. Secondary failure to treatment with oral antidiabetic agents in non-insulin-dependent diabetes. Diabetes Care 1986; 9: 129–33.
192. Samanta A, Burden achéal, Jones GR, Clarkson L. The effect of short term intensive insulin therapy in non-insulin-dependent diabetics who had failed on sulfonylurea therapy. Diabetes Res 1986; 3: 269–71.
193. Yki-Jarvinen H, Esko H, Eero H, Marja-Riitta T. Clinical benefits and mechanisms of a sustained response to intermittent insulin therapy in type 2 diabetic patients with secondary drug failure. Am J Med 1988; 84: 185–92.
194. Lev J, Zeidler A, Kumar D. Glyburide and glipizide in treatment of diabetic patients with secondary failures to tolazamide or chlorpropamide. Diabetes Care 1987; 10: 679–82.
195. Cohen KL, Harris S. Efficacy of glyburide in diabetics poorly controlled on first-generation oral hypoglycemies. Diabetes Care 1987; 10: 555–7.
196. Katz HM, Bissei G. Blood sugar lowering effects of chlorpropamide and tolbutamide: a double blind cooperative study. Diabetes 1965; 14: 650–7.
197. O'Sullivan DJ, Cashman WF. Blood glucose variations and clinical experience with glibenclamide in diabetes mellitus. Br Med J 1970; 2: 572–4.
198. Davidson M, Lewis AA, De Mowbray RR. Boucher BJ, Oakley NW. Metabolic and clinical effects of glibenclamide. Lancet 1970; 1: 57–61.
199. Glyburide and glipizide. Med Lett Drugs Ther 1984; 26: 79–80.
200. Kreisberg RA. The second-generation sulfonylureas: change or progress. Ann Intern Med 1985; 102: 125–6.
201. Groop L, Wahlin-Boll E, Groop PH, et al. Pharmacokinetics and metabolic effects of glibenclamide and glipizide in type 2 diabetics. J Clin Pharmacol 1985; 28: 697–704.
202. Frederiksen PK, Mogensen EF. A clinical comparison between glipizide and glibenclamide in the treatment of maturity onset diabetes: a controlled double-blind, cross-over study. Curr Ther Res 1982; 32: 1–7.
203. Sonksen PH, Lowy C, Perkins JR, West TE. Hormonal and metabolic effects of chlorpropamide, glibenclamide and placebo in a cross-over study in diabetics not controlled by diet alone. Diabetologia 1981; 20: 22–30.
204. Clarke BF, Campbell IW. Long-term comparative trial of glibenclamide and chlorpropamide in diet-failed, maturity-onset diabetics. Lancet 1975; 1: 246–8.
205. Ward EA, Lang DA, Phillips MR, Turner RC. Comparison of chlorpropamide and glibenclamide treatment of maturity-onset diabetes: control assessed by fasting plasma glucose concentrations. Diabetes Care 1981; 4: 293–5.
206. Moorhouse JA. A comparison of the effects of tolazamide and tolbutamide upon blood glucose and serum insulin and lipid levels in diabetic subjects. Can Med Assoc J 1967; 96: 536–9.
207. Lentini S, Bossini A, Pirola LC. A controlled clinical trial of a new oral hypoglycemic agent, glipizide (K 4024). Arzneimittelforschung 1972; 22: 1169–73.
208. Fineberg SE, Schneider SH. Glipizide versus tolbutamide, an open trial: effects on insulin secretory patterns and glucose concentrations. Diabetologia 1980; 18: 49–54.
209. Howard B. Lipoprotein metabolism in diabetes mellitus. J Lipid Res 1987; 28: 613–28.
210. Huupponen RK, Viikari JS, Saarimaa H. Correlation of serum lipids with diabetes control in sulfonylurea-treated diabetic patients. Diabetes Care 1984; 7: 575–8.
211. Lopes-Virella MF, Stone PG, Colwell JA. Serum high density lipoprotein in diabetic patients. Diabetologia 1977; 13: 285–91.
212. Lisch HJ, Sailer S. Lipoproteins patterns in diet, sulfonylurea, and insulin-treated diabetics. Diabetologia 1981; 20: 118–22.
213. Calvert GD, Graham JJ, Mannik T, Wise PH, Yeates RA. Effects of therapy on plasma-high-density-lipoprotein-cholesterol concentration in diabetes mellitus. Lancet 1978; 2: 66–8.
214. Kennedy AL, Lappin TR, Lavery TD, Hadden DR, Weaver JA, Montgomery DA. Relation of high-density lipoprotein cholesterol concentration to type of diabetes and its control. Br Med J 1978; 2: 1191–4.
215. Kasim SE, LeBoeuf RC, Rockett MJ, Page J, Keyser AJ. The effects of oral agent or insulin treatments on the plasma lipoproteins and the plasma lipoprotein lipase activator in diabetic patients. Horm Metab Res 1986; 18: 190–3.
216. Greenfield MS, Dobeme L, Rosenthal M, Vreman HJ, Reaven GM. Lipid metabolism in non-insulin-dependent diabetes mellitus: effects of glipizide therapy. Arch Intern Med 1982; 142: 1498–500.
217. Taskinen M, Beltz WF, Harper I, et al. Effects of NIDDM on very-low-density lipoprotein triglycéride and apolipoprotein metabolism: studies before and after sulfonylurea therapy. Diabetes 1986; 35: 1268–77.
218. Stenman S, Groop PH, Saloranta C, Toterman K, Fyhrqvist F, Groop L. Effects of the combination of insulin and glibenclamide in type II (non-insulin-dependent) diabetic patients with secondary failure to oral hypoglycaemic agents. Diabetologia 1988; 31: 206–13.
219. Osei K, O'Dorisio TM, Falko JM. Concomitant insulin and sulfonylurea therapy in patients with type II diabetes: effects on glycoregulation and lipid metabolism. Am J Med 1984; 77: 1002–9.
220. O'Donovan CJ. Analysis of long-term experience with tolbutamide (orinase) in the management of diabetes. Curr Ther Res 1959; 1: 69–87.
221. Pannekoek J. Insulin, glucagon and oral hypoglycaemic drugs. In: Dukes MNG, ed. Meyler's side effects of drugs: a survey of unwanted effects of drugs reported in 1972–1975. Vol. 8. Amsterdam: Excerpta Medica, 1975:904–27.
222. Glibenclamide: a review. Drugs 1971; 1: 116–40.
223. Gundersen K, Molony BA, Crim JA, Hearron AE Jr, Maile JP. Micronase® (glyburide): clinical overview. In: Rifkin H, ed. Micronase® glyburide: pharmacology and clinical evaluation. Amsterdam: Excerpta Medica, 1975:254–64.
224. Krans H. Insulin, glucagon and oral hypoglycaemic drugs. In: Dukes MNG, ed. Meyier's side effects of drugs: annual 3, 1979. Amsterdam: Excerpta Medica, 1979:343–53.
225. Emanueli A, Molari E, Pirola LC, Caputo G. Glipizide, a new sulfonylurea in the treatment of diabetes mellitus: summary of clinical experience in 1064 cases. Arzneimittelforschung 1972; 22: 1881–5.
226. Cerdino V, Persigli A, Calvert J, Soler J. Clinical evaluation of glipizide: results of a multicenter study in Spain. Rev Iberica Endocrinol 1975; 22: 43–60.
227. DCCT Research Group. Weight gain associated with intensive therapy in the Diabetes Control and Complications Trial. Diabetes 1988; 11: 567–73.
228. Welle S, Narr KS, Lockwood D. Effect of a sulfonylurea and insulin on energy expenditure in type II diabetes mellitus. J Clin Endocrinol Metab 1988; 66: 593–7.
229. Berger W. Incidence of severe sideeffects during therapy with sulfonylureas and biguanides. Horm Metab Res 1985; 17: Suppl 15: 111–5.
230. Kadowaki T, Hagura R, Kajinuma H, Kuzuya N, Yoshida S. Chlorpropamide-induced hyponatremia: incidence and risk factors. Diabetes Care 1983; 6: 468–71.
231. Sloan RW, Kreider RM, Luderer JR. The effects of chlorpropamide-hyponatremia on mental status in a nursing home population. J Fam Pract 1983; 16: 937–42.
232. Campbell IW. Metformin and the sulfonylureas: the comparative risk. Horm Metab Res 1985; Suppl 15: 105–11.
233. Wiholm BE, Westerholm B. Drug utilization and morbidity statistics for the evaluation of drug safety in Sweden. Acta Med Scand Suppl 1984; 683: 107–17.
234. Asplund K, Wiholm BE, Lithner F. Glibenclamide-associated hypoglycaemia: a report on 57 cases. Diabetologia 1983; 24: 412–7.
235. Seltzer HS. Drug-induced hypoglycemia: a review of 1418 cases. Endocrinol Metab Clin North Am 1989; 18: 163–83.
236. Berger W, Caduff F, Pasquel M, Rump A. Die relative Häufigkeit der schweren Sulfonylhamstoff-Hypoglykämie in den letzten 25 Jahren in der Schweiz: Resultat von zweigesamtschweizerischen Umfragen in dem Jahren 1969 und 1984. Schweiz Med Wochenschr 1986; 116: 145–51.
237. Ferner RE, Niel HA. Sulfonylureas and hypoglycaemia. Br Med J 1988; 296: 949–50.
238. Jennings AM, Wilson RM, Ward JD. Symptomatic hypoglycemia in NIDDM patients treated with oral hypoglycemic agents. Diabetes Care 1989; 12: 203–8.
239. Gerich JE. Glucose counterregulation and its impact on diabetes mellitus. Diabetes 1988; 37: 1608–17.
240. Kemball ML, Mclver C, Milner RD, Nourse CH, Schiff D, Tiernan JR. Neonatal hypoglycaemia in infants of diabetic mothers given sulfonylurea drugs in pregnancy. Arch Dis Child 1970; 45: 696–701.
241. Uraemic hypoglycaemia. Lancet 1986; 1: 660–1.
242. Campbell PJ, Gerich JE. Mechanisms of prevention, development, and reversal of hypoglycemia. Adv Intern Med 1988; 33: 205–30.
243. Alexander RW. Prolonged hypoglycemia following acetohexamide administration: report of two cases with impaired renal function. Diabetes 1966; 15: 362–4.
244. Rull JA, Lennhoff M. Prolonged and recurrent tolazamide-induced hypoglycemia: report of a case. Diabetes 1967; 16: 352–3.
245. Christensen LK, Hansen JM, Kristensen M. Sulphaphenazole-induced hypoglycaemic attacks in tolbutamide-treated diabetics. Lancet 1963; 2: 1298–301.
246. Field JB, Ohta M, Boyle C, Remer A. Potentiation of acetohexamide hypoglycemia by phenylbutazone. N Engl J Med 1967; 277: 889–94.
247. Brunova E, Slabochova Z, Platilova H, Pavlik F, Grafnetterova J, Dvoracek K. Interaction of tolbutamide and chloramphenicol in diabetic patients. Int J Clin Pharmacol Biopharm 1977; 15: 7–12.
248. Brown KF, Crooks MJ. Displacement of tolbutamide, glibenclamide and chlorpropamide from serum albumin by anionic drugs. Biochem Pharmacol 1976; 25: 1175–8.
249. Crooks MJ, Brown KF. Interaction of glipizide with human serum albumin. Biochem Pharmacol 1975; 24: 298–9.
250. Sartor G, Schersten B, Carlstrom S, Melander A, Norden A, Persson G. Ten-year follow-up of subjects with impaired glucose tolerance: prevention of diabetes by tolbutamide and diet regulation. Diabetes 1980; 29: 41–9.
251. Larkins RG. The use of oral hypoglycemic agents in the treatment of diabetes mellitus. Med J Aust 1987; 146: 477–80.
252. Lipson LG, Lipson M. The therapeutic approach to the obese maturity-onset diabetic patient. Arch Intern Med 1984; 144: 135–8.
253. Tomkins AM, Bloom A. Assessment of the need for continued oral therapy in diabetes. Br Med J 1972; 1: 649–51.
254. Lev-Ran A. Trial of placebo in long-term chlorpropamide-treated diabetics. Diabetologia 1974; 10: 197–200.
255. Allen BT, Feinglos MN. Combination insulin-sulfonylurea therapy in type II diabetes mellitus. South Med J 1987; 80: 1285–9.
256. Kyllastinen M. Sulfonylurea in combination with insulin therapy: does it make sense? A review. Ann Clin Res 1983; 15: Suppl 37: 29–32.
257. Hamelbeck H, Klein W, Zoltobrocki M, Schöffling K. GlibenclamidInsulin-Kombinationsbehandlung beim Sekundärversagen der Sulfonylharnstoff-Therapie. Dtsch Med Wochenschr 1982; 107: 1581–3.
258. Simonson DC, Delprato S, Castellino P, Groop L, DeFronzo RA. Effect of glyburide on glycemic control, insulin requirement, and glucose metabolism in insulin-treated diabetic patients. Diabetes 1987; 36: 136–46.
259. Longnecker MP, Elsenhans VD, Leiman SM, Owen OE, Boden G. Insulin and sulfonylurea agent in non-insulin-dependent diabetes mellitus. Arch Intern Med 1986; 146: 673–6.
260. Traumann KJ, Hösl W, Grom E, Wittemann G. Kombination von Insulin und S ulfonylharnstoffen bei der Therapie des Diabetes mellitus vom Erwach-senen-Typ. Dtsch Med Wochenschr 1982; 107: 180–4.
261. Mauerhoff T, Ketelslegers JM, Lambert AE. Effect of glibenclamide in insulin-treated diabetic patients with a residual insulin secretion. Diabete Metab 1986; 12: 34–8.
262. Quatraro A, Consoli G, Ceriello A, Giugliano D. Combined insulin and sulfonylurea therapy in non-insulin-dependent diabetics with secondary failure to oral drugs: a one year follow-up. Diabete Metab 1986; 12: 315–8.
263. Sachse G, Mäser E, Federlin K. Kombinationstherapie mit Insulin und Sulfonylharnstoffen bei Sekundärversagen der Sulfonylharnstofftherapie? Dtsch Med Wochenschr 1984; 109: 419–21.
264. Lins PE, Lundblad S, Persson-Trotzig E, Adamson U. Glibenclamide improves the response to insulin treatment in non-insulin-dependent diabetics with second failure to sulfonylurea therapy. Acta Med Scand 1988; 223: 171–9.
265. Gutniak M, Karlander SG, Efendic S. Glyburide decreases insulin requirement, increases β-cell response to mixed meal, and does not affect insulin sensitivity: effects of short- and long-term combined treatment in secondary failure to sulfonylurea. Diabetes Care 1987; 10: 545–54.
266. Kitabchi AE, Soria AG, Radparvar A, Lawson-Grant V. Combined therapy of insulin and tolazamide decreases insulin requirement and serum triglycerides in obese patients with noninsulin-dependent diabetes mellitus. Am J Med Sci 1987; 294: 10–4.
267. Lardinois CK, Liu GC, Reaven GM. Glyburide in non-insulin-dependent diabetes: its therapeutic effect in patients with disease poorly controlled by insulin alone. Arch Intern Med 1985; 145: 1028–32.
268. Castillo M, Scheen AJ, Paolisso G, Lefebvre PJ. The addition of glipizide to insulin therapy in type-II diabetic patients with secondary failure to sulfonylureas is useful only in the presence of a significant residual insulin secretion. Acta Endocrinol (Copenh) 1987; 116: 364–72.
269. Bieger WP, Dlugosch R, Rettenmeier A, et al. Trial of sulfonylurea in combination with insulin in the therapy of diabetes type I and II: evidence against a primary extrapancreatic receptor effect. Klin Wochenschr 1986; 62: 631–9.
270. Reich A, Abraira C, Lawrence AM. Combined glyburide and insulin therapy in type II diabetes. Diabetes Res 1987; 6: 99–104.
271. Holman RR, Steemson J, Turner RC. Sulphonylurea failure in type 2 diabetes: treatment with a basal insulin supplement. Diabetic Med 1987; 4: 457–62.
272. Garvey WT, Olefsky JM, Griffin J, Hamman RF, Kolterman OG. The effect of insulin treatment on insulin secretion and insulin action in type II diabetes mellitus. Diabetes 1985; 34: 222–34.
273. Williams RH, Palmer JP. Farewell to phenformin for treating diabetes mellitus. Ann Intern Med 1975; 83: 567–8.
274. Bailey CJ, Nattrass M. Treatment — metformin. Baillieres Clin Endocrinol Metab 1988; 2: 455–76.
275. Hermann LS. Metformin: a review of its pharmacological properties and therapeutic use. Diabete Metab 1979; 5: 233–45.
276. Vigneri R, Goldfine ID. Role of metformin in treatment of diabetes mellitus. Diabetes Care 1987; 10: 118–22.
277. Bailey CJ. Metformin revisited: its actions and indications for use. Diabetic Med 1988; 5: 315–20.
278. Schafer G. Biguanides: a review of history, pharmacodynamics and therapy. Diabete Metab 1983; 9: 148–63.
279. Pentikainen P, Neuvonen PJ, Penttila A. Pharmacokinetics of metformin after intravenous and oral administration to man. Eur J Clin Pharmacol 1979; 16: 195–202.
280. Tucker GT, Casey C, Phillips PJ, Connor H, Ward JD, Woods HF. Metformin kinetics in healthy subjects and in patients with diabetes mellitus. Br J Clin Pharmacol 1981; 12: 235–46.
281. Sirtori CR, Franceschini G, Galli-Kienle M, et al. Disposition of metformin (N,N-dimethylbiguanide) in man. Clin Pharmacol Ther 1978; 24: 683–93.
282. Jackson RA, Hawa MI, Jaspan JB, et al. Mechanism of metformin action in non-insulin-dependent diabetes. Diabetes 1987; 36: 632–40.
283. Nosadini R, Avogaro A, Trevisan R. et al. Effect of metformin on insulin-stimulated glucose turnover and insulin binding to receptors in type II diabetes. Diabetes Care 1987; 10: 62–7.
284. Frayn KN, Adnitt PI, Turner P. The hypoglycaemic action of metformin. Postgrad Med J 1971; 47: 777–80.
285. Meyer F, Ipaktchi M, Clauser H. Specific inhibition of gluconeogenesis by biguanides. Nature 1967; 213: 203–4.
286. Cook DE, Blair JB, Lardy HA. Mode of action of hypoglycemic agents. V. Studies with phenethylbiguanide in isolated perfused rat liver. J Biol Chem 1973; 248: 5272–7.
287. Haeckel R, Haeckel H. Inhibition of gluconeogenesis from lactate by phenylethylbiguanide in perfused guinea pig liver. Diabetologia 1972: 8: 117–24.
288. Prager R, Schemthaner G. Insulin receptor binding to monocytes, insulin secretion, and glucose tolerance following metformin treatment: results of a double-blind, cross-over study in type II diabetics. Diabetes 1983; 32: 1083–6.
289. Prager R, Schenthaner G, Graf H. Effect of metformin on peripheral glucose utilization in noninsulin-dependent diabetes mellitus. Metabolism 1987; 36: 774–6.
290. Nattrass M, Todd PG, Hinks L, Lloyd B, Alberti KGMM. Comparative effects of phenformin, metformin and glibenclamide on metabolic rhythms in maturity-onset diabetics. Diabetologia 1977; 13: 145–52.
291. Clarke BF, Duncan LJ. Comparison of chlorpropamide and metformin treatment on weight and blood-glucose response of uncontrolled obese diabetics. Lancet 1968; 1: 123–6.
292. Rains SG, Wilson GA, Richmond W, Elkeles RS. The effect of glibenclamide and metformin on serum lipoproteins in type 2 diabetes. Diabetic Med 1988; 5: 653–8.
293. Clarke BF, Duncan LJP. Combined metform in-chlorpropamide therapy in 108 diabetic sulphonylurea-failures. Lancet 1965; 1: 1248–51.
294. Fedele D, Tiengo A, Nosadini R, et al. Hypolipidemic effects of metformin in hyperprebetalipoproteinemia. Diabete Metab 1976; 2: 127–33.
295. Johnson DG, Bressler R. New pharmacologic approaches to the treatment of diabetes. Spec Top Endocrinol Metab 1984; 6: 163–92.
296. Turnan RW, Tutwiler GF, Joseph JM, Wallace NH. Hypoglycaemic and hypoketonaemic effects of single and repeated oral doses of methyl pamoxirate (methyl 2-tetradecyglycidate) in streptozotocin/alloxan-induced diabetic dogs Br J Pharmacol 1988; 94: 130–6.
297. Kashiwagi A, Harano Y, Suzuki M, et al. New alpha2-adrenergic blocker (DG-5128) improves insulin secretion and in vivo glucose disposal in NIDDM patients. Diabetes 1986; 35: 1085–9.
298. Chang AY, Gilchrist BJ, Wyse BM. Ciglitazone, a new hypoglycaemic agent. 3. Effect on glucose disposal and gluconeogenesis in vivo in C57BL/6J-ob/ob and -+/? mice. Diabetologia 1983; 25: 514–20.
299. Tutwiler G, Truman R, Joseph J, Mihan B, Fawthrop H, Brentzel H. Pharmacologic profile and insulin secretogogue effect of linogliride (McN-3935), a new orally effective hypoglycemic agent. Drug Dev Res 1986; 9: 273–92.
300. Clissold SP, Edwards C. Acarbose: a preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential. Drugs 1988; 35: 214–43.
301. Dimitriadis G, Karaiskos C, Raptis S. Effects of prolonged (6 months) αglucosidase inhibition on blood glucose control and insulin requirements in patients with insulin-dependent diabetes mellitus. Horm Metab Res 1986; 18: 253–5.
302. Johansen K. Acarbose treatment of sulfonylurea-treated non-insulin-dependent diabetics: a double-blind, cross-over comparison of an α-glucosidase inhibitor with metformin. Diabete Metab 1984; 10: 219–23.